drugset

drugset / Trial / NCT07695701

Cardiac Magnetic Resonance and Echocardiography Study With Acoramidis

NCT07695701 ↗

Phase 4 Not yet recruiting 150 enrolled Eidos Therapeutics, a BridgeBio company

NaSingle-groupOpen-labelTreatment

Summary

The study aims to evaluate the effect of acoramidis on cardiac functional and structural improvement in participants with ATTR-CM.

Timeline

Start: 2026-07
Primary completion: 2030-08
Completion: 2030-11

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Acoramidis	Unknown	712 mg	Oral

Indications